TEV: transferable data exclusivity voucher

The transferable data exclusivity voucher does not exist in current law. It is created by the agreed text of the new EU pharmaceutical regulation, adopted by the Council on 28 September 2026 and awaiting Parliament's final vote, as an incentive for developing priority antimicrobials. The idea is simple: a company that brings an eligible antimicrobial to market receives a voucher that adds twelve months of regulatory data protection to one centrally authorised product. The voucher can be applied to the holder's own product or transferred, so a small developer can sell it to a company with a high-revenue product nearing the end of its protection.

The voucher is the EU's answer to the economics of antimicrobials: a new antibiotic should be used sparingly, so it will not recover its development cost through sales. Rather than funding development directly, the package pays the developer with protection on another product, which in turn delays generic entry for that product by a year. The eligibility criteria for the antimicrobial, the conditions for transfer and the limits on the scheme are set in the agreed regulation text, and the published act in the Official Journal may change details. The Commission's 2023 proposal framed the voucher as a time-limited and capped instrument, and much of the negotiation between Parliament and Council concerned its cost to national health systems, so the final conditions should be read in the published act rather than in earlier drafts.

For regulatory and planning teams the voucher matters in two directions. Antimicrobial developers need to design their programmes and dossiers to meet the priority criteria from the start, since a product that narrowly misses them gets nothing. Holders of large products, and the generic companies that plan around them, need to watch which vouchers are granted and where they are applied, because a voucher can move the loss-of-exclusivity date of an unrelated product by twelve months with little notice.

Under the new pharma package (not yet in force), the voucher provisions apply from the regulation's entry into force under Article 187 of the agreed text, earlier than most of the package, which applies 24 months later; see antimicrobials changes.